Focused On-demand Library for Solute carrier family 22 member 12

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q96S37

UPID:
S22AC_HUMAN

ALTERNATIVE NAMES:
Organic anion transporter 4-like protein; Renal-specific transporter; Urate anion exchanger 1; Urate:anion antiporter SLC22A12

ALTERNATIVE UPACC:
Q96S37; B7WPG1; G3XAN7; Q19PF7; Q19PF8; Q19PF9; Q19PG0; Q6UXW3; Q96DT2

BACKGROUND:
The protein Solute carrier family 22 member 12, known by alternative names such as Renal-specific transporter and Urate:anion antiporter SLC22A12, is integral to urate transport in the kidneys. It exchanges urate for various anions, playing a key role in controlling blood uric acid levels and contributing to the body's ability to process waste products.

THERAPEUTIC SIGNIFICANCE:
Disruptions in the function of SLC22A12 are implicated in Hypouricemia renal 1, a disorder with significant renal implications, including acute and chronic renal failure. The exploration of SLC22A12's function and its genetic variants offers a promising avenue for the development of novel treatments for urate handling abnormalities and their associated renal complications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 863 of 8789